BioMarin Pharmaceutical (NASDAQ:BMRN) Given New $86.00 Price Target at Guggenheim

BioMarin Pharmaceutical (NASDAQ:BMRN) had its price target decreased by Guggenheim from $106.00 to $86.00 in a research report report published on Wednesday,Benzinga reports. Guggenheim currently has a buy rating on the biotechnology company’s stock.

Other equities research analysts have also recently issued reports about the company. Stifel Nicolaus set a $68.00 price target on BioMarin Pharmaceutical in a report on Tuesday. Oppenheimer decreased their target price on BioMarin Pharmaceutical from $98.00 to $95.00 and set an “outperform” rating on the stock in a research note on Tuesday. Royal Bank Of Canada restated a “sector perform” rating and issued a $66.00 price target on shares of BioMarin Pharmaceutical in a research note on Tuesday, October 28th. Piper Sandler reduced their price objective on shares of BioMarin Pharmaceutical from $122.00 to $84.00 and set an “overweight” rating on the stock in a research report on Friday, February 6th. Finally, Wells Fargo & Company boosted their target price on shares of BioMarin Pharmaceutical from $70.00 to $75.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. Fifteen equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, BioMarin Pharmaceutical currently has an average rating of “Moderate Buy” and an average price target of $87.43.

BioMarin Pharmaceutical Stock Performance

Shares of NASDAQ BMRN opened at $61.44 on Wednesday. The stock has a market cap of $11.80 billion, a PE ratio of 34.52, a price-to-earnings-growth ratio of 0.68 and a beta of 0.26. BioMarin Pharmaceutical has a 1 year low of $50.76 and a 1 year high of $73.51. The firm has a fifty day moving average price of $58.72 and a 200-day moving average price of $56.12. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.21 and a quick ratio of 3.10.

Institutional Investors Weigh In On BioMarin Pharmaceutical

Several large investors have recently bought and sold shares of the business. Norges Bank bought a new position in BioMarin Pharmaceutical during the fourth quarter valued at $447,572,000. AQR Capital Management LLC raised its position in shares of BioMarin Pharmaceutical by 90.7% during the 2nd quarter. AQR Capital Management LLC now owns 5,580,573 shares of the biotechnology company’s stock valued at $306,429,000 after buying an additional 2,654,768 shares in the last quarter. Vestal Point Capital LP lifted its holdings in shares of BioMarin Pharmaceutical by 261.4% in the 4th quarter. Vestal Point Capital LP now owns 3,000,000 shares of the biotechnology company’s stock valued at $178,290,000 after acquiring an additional 2,170,000 shares during the last quarter. Capital Research Global Investors lifted its holdings in shares of BioMarin Pharmaceutical by 547.5% in the 3rd quarter. Capital Research Global Investors now owns 2,537,596 shares of the biotechnology company’s stock valued at $137,436,000 after acquiring an additional 2,145,717 shares during the last quarter. Finally, Viking Global Investors LP grew its position in BioMarin Pharmaceutical by 13.8% in the second quarter. Viking Global Investors LP now owns 12,288,611 shares of the biotechnology company’s stock worth $675,505,000 after acquiring an additional 1,488,552 shares in the last quarter. Institutional investors own 98.71% of the company’s stock.

Key BioMarin Pharmaceutical News

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Q4 earnings beat and record/strong revenue growth driven by Voxzogo, which supports near-term fundamentals. Q4 Highlights
• Positive Sentiment: Sanford C. Bernstein raised its price target to $94 and keeps an “outperform” rating, signaling bullish conviction from a major shop. Bernstein PT Raise
• Positive Sentiment: TD Cowen/Phil Nadeau maintained a Buy rating with a $120 price target, highlighting confidence in multi‑year growth and recent strategic moves. TD Cowen Note
• Neutral Sentiment: Bank of America reiterated a Buy but trimmed its target to $97, reflecting confidence in long-term upside while acknowledging nearer-term pressures. BofA Note
• Neutral Sentiment: Management will present at four investor conferences in March, which could provide additional investor visibility and updates on pipeline strategy. Investor Conferences
• Neutral Sentiment: Public short-interest data for February is effectively zero/unclear (likely reporting artifact) and does not appear to be a driver of today’s move.
• Negative Sentiment: BioMarin said it will voluntarily withdraw Roctavian (its hemophilia gene therapy) from the market — a material strategic setback that raises questions about near- and medium-term revenue trajectory and risk profile. Roctavian Withdrawal
• Negative Sentiment: Several analysts trimmed targets or issued more cautious notes (Guggenheim lowered to $86, HC Wainwright cut to $55 and moved to Neutral), creating mixed sell-side signals and short-term pressure. Analyst Revisions

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.